Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)

Daiichi Sankyo

Status and phase

Completed

Phase 1

Conditions

Malignancies

Lymphoma

Treatments

Drug: CS-1008 (humanized anti-DR5 antibody)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00320827

CS1008-A-U101

Details and patient eligibility

About

This is a dose escalation study of CS-1008 (humanized anti-DR5 antibody) to determine the recommended Phase 2 dose and the maximum tolerated dose. Drug will be administered for six weeks and possibly up to 12 weeks depending on response.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically or cytologically diagnosed metastatic solid tumors or lymphomas (with no leukemic component) which are refractory to, not curable with, or not eligible for standard treatment(s).
Eighteen years of age or older
Eastern Cooperative Oncology Group (ECOG) performance status equal to or less than 2
Resolution of any toxic effects (except alopecia) of prior therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 grade of equal to or less than 1
Men and women of childbearing potential must be willing to consent to use effective contraception while on treatment and for at least 3 months thereafter.
All female patients of childbearing potential must have a negative pregnancy test (serum or urine) within 3 days prior to treatment
Patients must be fully informed about their illness and the investigational nature of the study protocol

Exclusion criteria

Anticipation of the need for a major surgical procedure or radiation therapy during the study
Treatment with chemotherapy, hormonal therapy, radiotherapy, major surgery, or any investigational agent within 4 weeks (6 weeks for nitrosoureas, mitomycin C, immunotherapy, biological therapy, or major surgery) of study enrollment
Cumulative radiation therapy to greater than 25% of the total bone marrow
Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) class III or IV congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other clinically significant thromboembolytic event; clinically significant pulmonary disease (e.g., severe chronic obstructive pulmonary disease [COPD] or asthma)
Patients with a clinically active brain metastasis (i.e., not treated or still requiring therapy with steroids or radiotherapy [RT]; or with progression 4 weeks after the completion of RT) or an uncontrolled seizure disorder, spinal cord compression, or carcinomatous meningitis
Clinically significant active infection which requires antibiotic therapy, or HIV-positive patients receiving antiretroviral therapy.
Chronic diarrhea, inflammatory bowel disease, or partial bowel obstruction